<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042142</url>
  </required_header>
  <id_info>
    <org_study_id>230279</org_study_id>
    <nct_id>NCT04042142</nct_id>
  </id_info>
  <brief_title>Glucagon Resistance in Patients With NAFLD</brief_title>
  <official_title>In-depth Studies of Glucagon Resistance on Hepatic Glucose, Fatty Acid and Triglyceride Kinetics and Generation of Toxic Lipid Intermediates in NAFLD and NASH.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Council for Independent Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose that the sensitivity to glucagon in hepatic lipid metabolism is&#xD;
      impaired in subjects with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis&#xD;
      (NASH). Moreover, they propose a dys-coordinated, reduced glucagon sensitivity in hepatic&#xD;
      lipid metabolism and endogen glucose production in patients with NAFLD and NASH compared with&#xD;
      healthy subjects and patients with simple steatosis. This reduced sensitivity may be the&#xD;
      basis of a more severe dyslipidemia and the production of increased concentrations of toxic&#xD;
      lipid intermediates in plasma and muscle tissue. The study will include healthy subjects with&#xD;
      obesity and subjects with simple steatosis and NASH, tested at basal glucagonemia and&#xD;
      moderate hyperglucagonemia to mimic insulin resistant levels during simultaneous somatostatin&#xD;
      infusion and replacement doses of insulin and growth hormone. Infusion of palmitate,&#xD;
      VLDL-triglyceride and glucose tracers in combination with indirect calorimetry as well as&#xD;
      skeletal and adipose tissue biopsies will be employed to assess free fatty acid and&#xD;
      VLDL-triglyceride kinetics (turnover, and oxidation) and hepatic fatty acid-esterification.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 5, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VLDL-triglyceride kinetics (appearance rate (µmol/min) and oxidation (µmol/min))</measure>
    <time_frame>30 minutes at steady-state</time_frame>
    <description>Ex vivo labeled VLDL [14C]-triolein tracer technique. Oxidation is measured by specific activity in exhaled air.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endogen glucose production (mmol/kg/min)</measure>
    <time_frame>30 minutes at steady-state</time_frame>
    <description>3-3H glucose tracer technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LPL-activity (lipoprotein lipase, µmol/h)</measure>
    <time_frame>30 minutes at steady-state</time_frame>
    <description>Measured by the 'glycerol-stabilized substrate' method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-triglyceride-fatty acid uptake in muscle and fatty tissue (%)</measure>
    <time_frame>30 minutes at steady-state</time_frame>
    <description>Measurement of fatty acid concentration and specific activity in muscle- and adipose tissue biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of relevant genes in tissues</measure>
    <time_frame>30 minutes at steady-state</time_frame>
    <description>PCR in muscle- and adipose tissue biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acid turnover (µmol/min)</measure>
    <time_frame>30 minutesat steady-state</time_frame>
    <description>Infusion af [9,10-3H] palmitate and measurement of specific activity in muscle and adipose tissue</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Healthy overweight subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MR spectroscopy verified no steatosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with non-alcoholic fatty liver disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MR spectroscopy verified steatosis, no steatohepatitis on liver biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with non-alcoholic steatohepatitis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MR spectroscopy verified steatosis, steatohepatitis on liver biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>glucagon</intervention_name>
    <description>Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.</description>
    <arm_group_label>Healthy overweight subjects</arm_group_label>
    <arm_group_label>Subjects with non-alcoholic fatty liver disease</arm_group_label>
    <arm_group_label>Subjects with non-alcoholic steatohepatitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 28 kg/m2&#xD;
&#xD;
          -  steatosis FF% &gt; 5,6% on MR spectroscopy for NAFLD and NASH groups&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active smoking&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  comorbidity other than hypertension and hyperlipidemia&#xD;
&#xD;
          -  participation in other radioactive isotope studies within the past 3-5 months&#xD;
             (depending on radiation dose)&#xD;
&#xD;
          -  blood donation (within 3 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>38 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Heebøll</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Danmark</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

